Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

This year. We're going Beyond.

Will the Pendal (ASX:PDL) share price swing in its favour?

The Pendal Group Ltd (ASX: PDL) share price may swing up on its March 2021 quarter update. The Pendal share price has started strongly, can it keep going north?

Pendal share price

Source: Rask Media PDL 2-year share price chart

Pendal achieves solid growth

Pendal advised its funds under management (FUM) for the March 2021 quarter is at $101.7 billion, rising by 4.4%.

The company recorded strong investment performance, which contributed $2.5 billion. Pendal also benefited from the depreciation of the Aussie dollar against key currencies, resulting in a positive impact of $0.9 billion.

Pendal achieved positive inflows of $0.9 billion, mainly due to improved net flows across the UK and Europe.

Nick Good, the CEO of Pendal, highlighted that it was able to capitalise on the recent market rotation from growth to value.

The CEO sounds optimistic about Pendal’s position to take advantage of improved economic conditions in the future.

Is Pendal a one-way pendulum?

Nick Good’s comment about the shift in market sentiment towards value is encouraging. Why so?

I believe his comment is an indicator of Pendal’s measured and disciplined investment approach.

Such an approach aligns with one key principle of the Rask Investment Philosophy, that the stock market is a vehicle for transferring wealth from the impatient to the patient.

Investors should consider whether this green patch in the market is sustainable and how Pendal’s investment philosophy stands up in a bear market.

If you are interested in other ASX growth shares,  I’d recommend signing up for a free Rask account to gain access to our stock reports.

Got $1,000? Try our #1 growth stock...

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or enter your email below. We'll send you the report.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Got $1,000? Try this...

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or the button below. We'll email you the report.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading: